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The multiple actions of somatostatin are mediated by specific membrane-bound receptors
present in all somatostatin target tissues, such as brain, pituitary, pancreas, and gastrointestinal
tract. Three different types of tissues in the human gastrointestinal tract express somatostatin
receptors: (1) the gastrointestinal mucosa, (2) the peripheral nervous system, and (3) the
gut-associated lymphoid tissue, where the receptors are preferentially located in germinal
centers. In all these cases, somatostatin binding is of high affinity and specific for bioactive
somatostatin analogs.
Somatostatin receptors are also expressed in pathological states, particularly in neuroendo-
crine tumors of the gastrointestinal tract. Ninety percent of the carcinoids and a majority of
islet-cell carcinomas, including their metastases, usually have a high density of somatostatin
receptors. Only 10 percent of the colorectal carcinomas and none of the exocrine pancreatic
carcinomas, however, contain somatostatin receptors.
The somatostatin receptors in tumors are identified with in vitro binding methods or with in
vivo imaging techniques; the latter allow the precise localization of the tumors and their
metastases in the patients. Since somatostatin receptors in gastroenteropancreatic tumors are
functional, their identification can be used to assess the therapeutic efficacy of octreotide to
inhibit excessive hormone release in the patients.
INTRODUCTION
Somatostatin (SS) is a cyclic 14-amino acid peptide with wide distribution in the
body and multiple sites ofaction [1]. SS and anotherbiologically active SS, SS-28, are
processedthrough differential splicingfromapre-prosomatostatinprecursor. Whereas
SS was originally purified from hypothalamic tissue, it has since been identified in
several other brain regions, in the peripheral nervous system, in the endocrine
pancreas, in the thyroid, and in the gut.
SS is a very strong inhibitor ofseveral key functions in the body [1]. It inhibits the
secretion of growth hormone and thyrotropin; in the pancreas, it inhibits glucagon
and insulin; in the brain, it exhibits a number of actions compatible with a role as
neurotransmitter [2]. In lymphoid tissues, it inhibits immunoglobulin synthesis and
lymphocyte proliferation. In the gastrointestinal system, SS is known to inhibit the
secretion of all major gastrointestinal hormones, to inhibit gastric and intestinal
motility, intestinal absorption, and gastric acid secretion.
SS induces these physiological effects by interacting with cell surface receptors in
target tissues. The presence ofhigh-affinity, specific SS receptors has been observed
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FIG. 1. SS mRNA in healthy rat gastric muco-
'3., < 'X',a',' .sa. A.Hematoxylin-eosin stained section. Bar =
1 mm. B. Autoradiogram showing SS mRNA,
using in situ hybridization. The limits of the mu-
cosa are drawn in black. The darkregions are spots
- representing areaswith high densities ofhybridiza-
tion signal. C.Autoradiogram showing the lack
--- -.;;;->>^l '> > -- of hybridization signal when twentyfold excess of
-, -- .2 ; ;;; unlabeled probe is co-hybridized with the labeled
s^- ~ - : :-;^ probe.
in such tissues as the brain, pituitary, adrenal gland, endocrine and exocrine
pancreas, gut, and lymphoid tissue. Through these specific SS receptors, SS has been
shown to inhibit adenylate cyclase activity, resulting in a decrease in intracellular
cyclic AMP, as well as a decrease of Ca2+ conductance and an increase of K+
conductance. Most, if not all, of these functions appear to be mediated by pertussis
toxin-sensitive GTP-binding proteins [3]. Moreover, in certain tissues, such as rat
pancreatic acinar cells, SS was shown to stimulate a low-molecular-mass phosphoryl
protein tyrosine phosphatase [4].
SS RECEPTORS IN THE GASTROINTESTINAL TRACT
SS as well as SS receptors are present in the healthy gastric mucosa. As shown in
Fig. 1, SS mRNA is found abundantly by in situ hybridization techniques [5] in most
layers of the rat gastric mucosa. In the same tissue, it is also possible to detect high
numbers of SS receptors. These receptors are of high affinity, with a dissociation
constant (KD) in the nanomolar range, and they are specific for SS, since only
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FIG. 2. Effect of SS analogs on SS
binding in tissue sections from rat gas-
tric mucosa. Displacement curve of 1251-
[Tyr3]-octreotide in tissue sections
incubatedwith30,000cpm/100 pulradio-
ligand and increasing concentrations of
[Tyr3]-octreotide (0) or 100 nM of the
biologically inactive SS analogSS-28 (1-
12) (O).
biologically active SS analogs, but not inactive SS analogs or unrelated peptides, are
able to displace SS radioligands, as shown in Fig. 2, for the gastric rat mucosa. Figure
3 shows an example of the distribution of these SS receptors in the rat gastric
mucosa, using 1251-[Tyr3]-octreotide as radioligand. Many of these receptors are
likely to be localized on parietal cells: indeed, high-affinity SS receptors were
identified in a canine parietal cell preparation [6]; in this model, SS inhibits, dose .pop<ot7?5,-ffisi,,,o_ti-*;
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FIG. 3. SS receptors in the rat gastric mucosa. A.
Hematoxylin-eosin stained section. Bar = 1 mm. B. Auto-
radiogram showing total binding of 1251-[Tyr3]-octreo-
tide. C. Autoradiogram showing nonspecific binding of
125I-[Tyr3]-octreotide, in presence of 10-6M unlabeled [Tyr3]-
octreotide. SS receptors are located in the major part of
the mucosa.
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FIG. 4. SS receptors in a biopsy of human gastric mucosa.
-3i;.>W.^;. .: >t;S*, < ^ (Tissue was obtained from F. Halter.) A. Hematoxylin-
eosin stained section. Bar= 1 mm. B. Autoradiogram
8 * .<. . showing total binding of 125I-[Tyr3]-octreotide. C. Auto-
radiogram showing nonspecific binding of 1251-[Tyr3]-octreo-
tide (in the presence of 106M [Tyr3]-octreotide).
dependently, parietal cell activity stimulated byvarious secretagogues [6,7]. Accord-
ing to otherfunctional studies, however, SS receptors are also likely tobe localized in
other cell types of the gastric mucosa, such as the gastrin-producing cells and the
histamine-producing enterochromaffine-like (ECL) cells [8,9; see also papers by
MakhloufandbySoll, inthis symposium]. We have recently had strong evidence that
high-affinity SS receptors are located on ECL cells [10]; indeed, the ECL tumors
originating spontaneously, or after H2-receptor blocker (loxtidine) treatment, in the
stomach of the mastomys mouse express a high density of SS receptors. Since these
tumors are highly differentiated and contain ECLcells exclusively, it isprobable that
healthy mucosal ECL cells would also express SS receptors. These data imply,
therefore, an important role of SS in the gastric physiology, in particular through
regulation ofhistamine secretion.
In addition to the above-mentioned membrane-bound SS receptors, cytosolic SS
receptors were also reported [11] ingastric mucosa. Their role remains unclear.
The presence of SS receptors cannot only be demonstrated in the gastric mucosa
ofexperimental animals, but also in man. Figure 4 shows SS receptors in the mucosa
of a biopsy taken from a human stomach. The number ofSS receptors appears to be
lower in human than in rat gastric mucosa; however, a greatervariability in receptor
density is observed in human than in rat tissue. Technical reasons may, in part, be
responsible for that fact, since the conditions for obtaining human samples may
sometimes be suboptimal.
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FIG. 5. SS receptors in an appendix from a child. (Tissue
was obtained from J. Gebbers.) A. Hematoxylin-eosin
stained section showing lymphatic follicles with germinal
centers and intestinal mucosa. Bar = 1 mm. B.Autoradio-
gram showing total binding of 125I-[Tyr3]-octreotide. Germi-
nal centers are labeled (arrows) as well as intestinal mucosa
(m). C. Nonspecific binding.
High-affinity SS receptors are also found in the lower humangastrointestinal tract.
They can be identified, for instance, in the mucosa ofthe ileum, jejunum, and colon
[12,13]. Their function there is not well established; they may mediate the SS
inhibition of peptide secretion from endocrine cells, as described for most other
parts of the gastrointestinal tract. More specifically, they may inhibit the intestinal
fluid secretion induced by various peptides (VIP, glucagon) in the jejunum and the
colon [14-16]. As expected, SS receptors are notonlyfound in the mucosabut also in
the plexus myentericus and plexus submucosus [12], where SS has been shown to
inhibit cholinergic transmission [17]. Moreover, SS receptors are localized in the
gut-associated lymphoid tissue, as recently reported [12], and are shown in an
example in Fig. 5. In this study, we have evaluated SS receptors in four human
gut-associated lymphoid tissues, namely, palatine tonsils, ileal Peyer patches, vermi-
form appendix, and colonic solitary lymphatic follicles, using receptor autoradiogra-
phy on tissue sections incubatedwith l251-[Tyr3]-octreotide [12]. All four tissueswere
somatostatin receptor-positive; the receptors were preferentially located in the
germinal centers, with the luminal part ofthe center more strongly labeled than the
basal part. The corona of the follicles and the primary follicles without germinal
centers did not display somatostatin receptors. The receptors were of high affinity
and specific for somatostatin. Displacement bynanomolarconcentrations ofsomato-
statin-14, somatostatin-28, and octreotide wasobserved, aswell as GTP dependency.
These data suggest strongly that the germinal centers ofthe gut-associated lymphoid
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TABLE 1
Incidence ofSomatostatin Receptors in Various Gut Tumors
Presence ofSS Receptors
Tumor Type (% ofPositive Cases)
GEPtumors
a. Islet-cell carcinomas
Insulinomas 8/11 (72)
Vipomas 7/8 (87)
Gastrinomas 5/5 (100)
Glucagonomas 3/3 (100)
GRF-omas 4/4 (100)
Non-functioning ICC 4/4 (100)
b. Carcinoids 66/81 (81)
Exocrinepancreatic carcinomas 0/12 (0)
Colonic carcinomas 3/26 (11)
tissue (GALT) are a site ofaction ofsomatostatin; possibly it mediates antiprolifera-
tive effects and inhibits immunoglobulin synthesis in the activated lymphoid cells
[12]. The human gut, therefore, represents a multi-faceted target for somatostatin
action, in which at least three different tissues, namely, mucosa, nerve plexus, and
lymphoid tissue, are involved.
Considering the increasing importance of immuno-neuroendocrine interactions
[18], it maybe speculated that these three SS receptor-containing tissues are, in fact,
integratedwithin a SS regulatory system ofa higher hierarchy. The studies by Felten
et al. [19] and Feher et al. [20] show an extensive noradrenergic and somatostatiner-
gic innervation ofthe lymphoid tissue, including the GALT. Therefore, it is conceiv-
able that the peripheral nervous system, including SS-containing nerve fibers, plays
an integrative role for immuno-neuroendocrine functions.
SS RECEPTORS IN HUMAN TUMORS
Remarkably, SS receptors havebeen observed notonlyin normal SS target tissues,
but also in several types of human cancer [21]. The receptors occur in most
neuroendocrine neoplasms and also in tumors ofthe central nervous system, breast,
and lung; they are, in addition, expressed by most lymphomas and renal cell cancers.
The presence of SS receptors may be, for certain tumor types, a pathobiochemical
marker ofpredictive value for the efficacy ofSS analog therapy [22], while, in others,
it may be of prognostic significance [23]. Moreover, these SS receptors can be
visualized in vivo with gamma-camera scanning techniques, making possible the
precise localization ofprimary and metastatic tumor sites [24,25].
SSReceptors in Hormone-Producing Gastroenteropancreatic Tumors
Avery high incidence ofhomogeneously distributed SS receptors is found in most
hormone-producing gastroenteropancreatic (GEP) tumors [26,27] (Table 1). Eighty-
one percent of the carcinoids tested (n = 81) were SS receptor-positive. A typical
case,with high density ofreceptors located preferentially in the tumorcells, is shown
in Fig. 6, where it can be observed that the receptor density in the carcinoid tumor
cells is much higher than in the surrounding healthy mucosa (see also Fig. 4).
Interestingly, the presence of SS receptors in a tumor may be related to its
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FIG. 6. SS receptors on intestinal carcinoid
': ,'tumor. (Tumor was obtained from L.
Kvols.) A. Hematoxylin-eosin stained section.
Bar = 1 mm. B. Autoradiogram showing to-
;. tal binding of 1251-[Tyr3]-octreotide. Tu tumor;
m, mucosa. C. Autoradiogram showing non-
c5'* -::specific binding (in the presence of 10-6M [Tyr3]-
:s: ;.ioctreotide). Notice the very high receptor
;<.;/ > : -;-.: - density in the tumor compared to the low density
in the mucosa.
differentiation state: forinstance, most ofthe SS receptor-negative carcinoidsbelong
to the less differentiated atypical carcinoids [27]; these are often bronchial carci-
noids, whereas intestinal carcinoids usually are receptor-positive. Also, most of the
islet-cell carcinomas (ICC) have SS receptors (Table 1). Whereas all gastrinomas,
glucagonomas, GRF-omas, and non-functioning ICC tested possess SS receptors, 87
percent of vipomas, and 72 percent of insulinomas were receptor-positive. Here
again, a high density of SS receptors is located in tumor tissue, well delimited from
surrounding tissue. Carcinoid and ICC SS receptors have the same biochemical
characteristics as SS receptors in healthy target tissues.
We have demonstrated that virtually all metastases of SS receptor-positive GEP
tumors are positive. Such homogeneous biological properties of primary and meta-
static lesions in regard to SS receptors have important therapeutic and diagnostic
consequences. The primary tumor, as well as its metastases, should be equally
sensitive to somatostatin therapy. This concept led us to develop a method of
analyzing the SS receptor status in patients with GEP tumors by measuring SS
receptors with autoradiography on small-needle biopsies from liver metastases [27].
By this method, the functionality of these tumoral SS receptors can be investigated;JEAN-CLAUDE REUBI
in 31 cases ofGEP tumors, a highly significant correlation was found between the SS
receptor status and the ability ofoctreotide to inhibit in vivo hormone secretion [27;
see also paperby Kvols et al. in this symposium]. Interestingly, some ofthese tumors,
in particular insulinomas, may bear an SS receptor subtype [27]. Such SS receptor
subtypes have been identified pharmacologically in the rat and the human brain by
mean of their differential affinity for certain somatostatin analogs [28-30]. Octreo-
tide, for example, can differentiate between two SS receptor types, one having a high
affinity for octreotide (SS1-R), the other a low affinity for octreotide (SS2-R). The
ratio between SSI-R and SS2-R varies among brain regions. Whereas a majority of
brain structures contain mainlySS,-R, the substantia nigra contains mainly SS2-R. In
turn, a majority of receptor-positive GEP tumors expressed the SSI-R subtype, but
some tumors expressed the SS2-R subtype. Those tumors included one-third of
insulinomas: they had SS receptors with low affinity for octreotide and high affinity
for SS-14 and SS-28, and their insulin release was inhibited onlyby SS-14 and SS-28,
but not by octreotide, in vitro aswell asin vivo [31]. In carcinoids, less than 10 percent
of the SS receptor-positive cases were expressing SS2-R. Recently, the cloning and
sequencing ofgenes encoding three different SS receptor subtypes (SSTR1, SSTR2,
and SSTR3) has been reported [32,33]. Preliminary studies in the brain tissue
suggest that SSTR1 and SSTR2could correspond to thepharmacologicallyidentified
SS2 and SS, receptor subtypes, respectively [34,35]. The presence of SS receptor
subtypes on tumors may have clinical implications. Indeed, those tumors with SS2-R
subtypes may react poorly, therapeutically, to octreotide, and they will not be
visualized in vivo with radiolabeled octreotide. The knowledge of SS receptor
subtypes may lead to the development ofsubtype-specific somatostatin analogs to be
used for selected and new indications.
Therefore, SS receptors in GEP tumors are the probable molecular basis for
hormone release inhibition by SS and, as such, relevant to the therapeutic efficacy of
octreotide. Additional functions ofSS may, however, be mediated by SS receptors in
these tumors: there are data from animal tumor models and cultured tumor cell
lines, i.e., in SS receptor-positive insulinomas or carcinoids, demonstratingthat SS or
octreotide has an antiproliferative action, with a 50 percent growth inhibition being
reported [36,37]. In patients with GEP tumors, however, such an antiproliferative
effect of chronic SS analog therapy and its exact site of action remain difficult to
evaluate. Recently, in pituitary tumor cells, it was possible to observe a dissociation
between antiproliferative and antihormonal effects of SS [38]. Both effects may be
mediated by different SS receptor subtypes.
SSReceptors in OtherGastrointestinal Tumors
Unfortunately, SS receptors seem not to be expressed frequently in undifferenti-
ated pancreatic and colonic carcinomas. We have not identified any SS receptors in
the 12 human exocrine pancreatic carcinomas tested [39]. We and others have,
however, found a small percentage of primary human colonic cancers to be SS
receptor-positive [13,21,40]. The lack of SS receptors in pancreatic carcinomas may
be a possible explanation for the inefficacy of octreotide in the treatment of these
tumors [41].
It is interesting to note that some, but not all [42], of the animal and human
transplanted tumors or cell lines derived from exocrine pancreatic and colonic
carcinomas may have high densities offunctional SS receptors [36,39].
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IN VIVO LOCALIZATION OF SS RECEPTOR-POSITIVE TUMORS
The high density ofSS receptors in many human tumors offers attractive possibili-
ties for their detectionin vivo. This result can be achieved by intravenous injection of
1231-[Tyr3]-octreotide or "11In-DTPA-octreotide in patients suspected of having SS
receptor-positive tumors [24,25,37,43]; such tumors are then localized with planar
and ECT images obtained bymeans ofagamma camera. With thismethod, hot spots
representing radioligand binding on SS receptor-positive tumors are visualized; the
hot spots thus identified represent SS receptor-containing tumors, since there is a
highly significant correlation in human tumors between the frequency ofSS receptor
positivity found by in vitro methods and by in vivo imaging. Indeed, most growth
hormone and thyrotropin-secreting pituitary adenomas, most carcinoids and islet-
cell carcinomas, all meningiomas, mostglomus tumors, and manyneuroblastomas, as
well as several breast tumors and small-cell lungcarcinomas, includingtheirmetasta-
ses, have alsobeenvisualized in vivo [37]. Moreover, we haverecentlyconfirmedthat,
in virtually all tumor patients with receptor-positive scans who later underwent
operative biopsies, the hot spots identified in vivo corresponded to SS receptor-
positive tumors, as measured with in vitro binding techniques [37]. These findings
clearly demonstrate the specificity of the in vivo imaging method and confirm the in
vitro findings that several tumors and their metastases contain high densities of SS
receptors. Thein vivo labeling oftumors, in particular ofthe SS receptor-dense GEP
tumors, opensverypromising new avenues fordiagnosis and, ultimately, fortherapy,
CONCLUSIONS
SS receptors in the gastrointestinal tract, localized in various different tissues and
cell types, aremediatingthe extremelycomplexand notyetfullyunderstoodmultiple
functions of SS in this organ. Eventually, future research may discover that these
different functions are mediatedbyselective SS receptor subtypes; as a consequence,
subtype-specific analogs may be developed with selective therapeutic indications.
This process, in turn, may enlarge the present clinical applications of SS analogs in
SS receptor-positive tumors and in non-malignant pathologies, both as diagnostic
and as therapeutic tools.
More generally, the discovery ofSS receptors in gastrointestinal tumors and their
clinical implications suggest that other peptide receptors may also play a role as
tumor markers. We already know that a large number of peptide receptors, i.e.,
gastrin, bombesin, VIP, CCK, or tachykinin receptors, can be expressed by gastroin-
testinal tumor cell lines or primary tumors; it can be foreseen that a similar
development, as in the SS field, may occur in relation to one or the other of these
peptides. Ideally, high expression of a peptide receptor should be identified in
tumors lacking SS receptors, i.e., colonic or pancreatic carcinomas, in order to
complete the diagnostic spectrum. As a prerequisite, small-sized and stable analogs
ofthese peptides need tobe developed in order tomake available successful markers
for these putative peptide receptors, not only for in vitro studies, but also for the in
vivo visualization ofthe tumors in patients.
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